Cra Intl Inc Stock Price, News & Analysis

Charles River Associates (NASDAQ: CRAI) will present at the Sidoti & Company Virtual Investor Conference on June 23, 2021. The presentation will be led by Paul Maleh, President and CEO, at 9:15 a.m. ET. A live webcast is accessible on the Company's investor relations website, allowing online attendees to engage in a virtual Q&A session. Maleh and Chad Holmes, Chief Corporate Development Officer, will also hold one-on-one meetings with investors. This event highlights CRA's expertise in economic, financial, and management consulting services.

Charles River Associates (NASDAQ: CRAI) will take part in the 2021 East Coast IDEAS Investor Conference on June 16, 2021. Key executives, including President Paul Maleh, CFO Daniel Mahoney, and Chief Corporate Development Officer Chad Holmes, will hold one-on-one meetings with investors. CRA specializes in economic, financial, and management consulting services, advising clients on litigation, regulatory matters, and business strategy. Founded in 1965 and headquartered in Boston, CRA has a global presence and offers expert solutions to complex problems.

Charles River Associates (NASDAQ: CRAI) announced the appointment of Daniel Roffman as vice president in the Forensic Services Practice. Roffman, with over 20 years of experience in digital forensics and information security, aims to enhance the company's capabilities in high-stakes cyber investigations. His background includes leadership roles at an international consulting firm and the U.S. Department of Justice. CRA’s Forensic Services Practice, known for its expertise in fraud and cyber incident response, is ISO 27001 certified, demonstrating a commitment to client information security.

Charles River Associates (NASDAQ: CRAI) reported a record quarterly revenue of $146.5 million for the fiscal first quarter ended April 3, 2021, reflecting a 16.1% year-over-year increase. Key drivers of growth included a 4.8% rise in headcount and a 76% utilization rate. Net income surged 62.4% to $10.5 million, while earnings per diluted share rose 67.5% to $1.34. CRA returned $11.7 million to shareholders through dividends and share repurchases. The company also raised its revenue guidance for the full year to between $550 million and $570 million.

Charles River Associates (NASDAQ: CRAI) has declared a quarterly cash dividend of $0.26 per common share, payable on June 11, 2021, to shareholders recorded by the close of business on May 25, 2021. This decision reflects the company's commitment to returning value to its shareholders. CRAI aims to continue its dividend payments, which are subject to the discretion of its Board of Directors. The firm specializes in economic, financial, and management consulting services, advising clients on critical business strategies.

Charles River Associates (NASDAQ:CRAI) has appointed Raquel Tamez as the first Chief Inclusion and Engagement Officer, effective June 1. This move aims to enhance the firm's commitment to diversity, equity, and inclusion (DE&I) initiatives globally. Tamez, previously CEO of the Society of Hispanic Professional Engineers, brings extensive experience in DE&I and legal expertise. CRA's President, Paul Maleh, expressed confidence that Tamez's leadership will strengthen the company's culture and better align it with client and community needs.

Charles River Associates (NASDAQ: CRAI) will host a webcast of its Q1 2021 financial results conference call on May 6, 2021, at 10:00 a.m. ET. The call will feature insights from key executives, including President and CEO Paul Maleh, CFO Daniel Mahoney, and Chief Corporate Development Officer Chad Holmes. Investors can access the live webcast through the 'Investor Relations' section of CRA's website and will have the opportunity to listen via telephone. An archived version will be available for one year post-event.

Charles River Associates (NASDAQ: CRAI) has appointed Tony Bower as Vice President in its Life Sciences practice, based in San Francisco. Bower brings 25 years of experience in market access, pricing strategy, and outcomes research, having previously worked with notable companies like Amgen and Synageva Biopharma. His expertise will enhance CRA's capabilities to assist clients in healthcare and technology. CRA's Life Sciences Practice focuses on biotech and pharmaceutical clients, providing analytical and strategic support.